Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07447206

Vascular Intervention Strategies Trial for Alzheimer's

The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hypertension Cardiovascular Diseases Dementia Risk Factors Dyslipidemias Hypercholesterolemia Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Clinical Sciences Building (CSC)

Los Angeles, California, 90033, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • APOE ε4 carrier (homozygote or heterozygote)
  • LDL-C of 100-250 mg/dL
  • Systolic blood Pressure (SBP) 130-180 mm Hg
  • Age 50-75 years
  • Fluency in English
  • No dementia based on medical record review
  • Male or post-menopausal female

Exclusion criteria

  • One minute standing SBP < 110 mm Hg
  • Arm circumference prevents from accurate BP measurement with use of available devices
  • Lost weight of > 10% unintendedly (within the past 6 months),
  • Contraindications to blood pressure and cholesterol lowering medications
  • Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
  • Evidence of dementia based on medical record review
  • Living in a skilled nursing or rehabilitation facility
  • Receiving palliative or hospice care
  • Bipolar illness or schizophrenia
  • Drug or alcohol disorder
  • Receiving chronic opioid therapy
  • Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
  • Severe loss of visual, hearing or communication ability
  • Organ transplant
  • History of stroke, symptomatic HF or left ventricular ejection fraction < 35%
  • ESRD or eGFR < 20 ml/min /1.73m2
  • Does not consent to be contacted or to have their medical record reviewed for research purposes
  • Concurrent participation in another clinical trial

Treatment and study plan

Angiotensin Receptor Blockers (ARBs)

Drug

Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).

Hydrophilic Statins or Non-Statin Alternative

Drug

Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.

Primary outcomes

  1. Blood Pressure Control

    Time frame: Baseline to 6 months

    Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.

Secondary outcomes

  1. Lipid Level Changes

    Time frame: Baseline to 6 months

    Change in LDL cholesterol (mg/dL) from baseline to 6 months.

  2. Feasibility Metrics

    Time frame: Study duration (6 months)

    adherence to prescribed medications (%).

Study contacts

Contact information is provided by the study sponsor or research team.

Hussein Yassine, MD

CONTACT

[email protected]

(323) 442-0272

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Registry information

Official study title

Vascular Intervention Strategies Trial for Alzheimer's (VISTA)

Acronym: VISTA

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Mar 3, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.